Drug General Information (ID: DDIV12LS9U)
Drug Name			Bivalirudin		Drug Info		Sugammadex		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antithrombotic Agents				Anesthetics
Structure

Mechanism of Bivalirudin-Sugammadex Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Bivalirudin				Sugammadex
Mechanism		Risk of bleeding Anticoagulant				Risk of bleeding Potentiate the effects of anticoagulants
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Bivalirudin and Sugammadex

Recommended Action
Management		Hemostasis and coagulation parameters should be closely monitored when sugammadex is administered to patients receiving therapeutic anticoagulation for a preexisting or comorbid condition patients who have received thromboprophylaxis drugs other than heparin and LMWH or patients who have received thromboprophylaxis with heparin or LMWH and subsequently administered 16 mg/kg of sugammadex.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Bridion (sugammadex). Merck &amp Company Inc, Whitehouse Station, NJ.